Key Takeaways
- Margin shock from raw material spike: EBITDA margin compressed to ~17% as solvent and chemical prices surged 2–3x, changing hourly, and could not be passed through on pre-existing orders. Management calls it a once-in-a-lifetime event and expects normalization to 25–27% by Q2–Q3 FY27.
- Revenue jump is acquisition-led: Total income rose to ₹87.62 crore from ₹33.31 crore YoY, driven largely by consolidation of Remember India, Apiqo, and Bizotic, while standalone Anlon revenue declined QoQ due to extended production campaign cycles.
- FY27 revenue guidance held at ₹350–400 crore: The full-year target is maintained, with H2 expected to be stronger than H1 on a roughly 45:55 split, and the fine chemical business already fully booked.
- Three new subsidiaries signal strategic breadth: Anlon Biologics (peptides, biosimilars) and Anlon Medicare (surgical implants) were incorporated, while Remember India adds finished dosage formulations, creating a pain-management-to-biologics ecosystem.
- What to watch next quarter: Whether the promised margin recovery to 25–27% materializes in Q2, progress on the share swap to make Apiqo and Bizotic wholly-owned, and any update on Remember India’s commercial revenue timeline and peak EBITDA potential.
Margin Compression: The Raw Material Shock
- Petroleum-driven input costs spiked without warning: Solvent and chemical prices, which form ~40% of API manufacturing cost, rose two to three times versus pre-war levels and began changing every day, making cost forecasting impossible.
- Price pass-through was blocked by existing commitments: Orders already in hand before the spike could not be repriced because the company deals with only 10–15 B2B customers and chose to absorb the hit to maintain credibility and long-term relationships. Price increases were secured only in subsequent orders.
- Currency and freight compounded the pressure: The INR moved from 91 to 96 within a month, and freight costs added further strain, all landing in the same quarter.
- Remember India consolidation added a structural drag: The newly acquired formulation subsidiary is in an investment and turnaround phase with no operational activity yet, contributing depreciation and other costs of ~₹1.29 crore that weighed on EBITDA.
- Gross margin volatility was the primary driver: Operating expenses and employee costs remained in balance; the entire EBITDA margin compression flowed from the gross margin line.
- Management absorbed the hit deliberately, then renegotiated: The company supplied at contracted prices through April to honor commitments, then subsequently asked customers for price increases, with the benefit expected to flow into H1 results.
Punit Rasadia: "When you are going to buy the raw materials, you have to pay the as per the current market price. But while you are maintaining the relation with your customers, because we are dealing in the B2B business, so you hardly have 10 to 15 customers. So, you cannot go to your customer every day and ask them to change the prices depend on the prices of crude. At certain level you have to maintain your credibility also, so if your margin is getting affected then also, we have to supply."
Revenue Composition & Seasonality
- Standalone Anlon revenue declined QoQ despite full capacity: Production campaign cycles for selected products exceeded 30–45 days, so revenue from those batches did not reflect in Q1; management says H1 will show the exact picture and advises comparing H1 vs H2 rather than quarter-on-quarter.
- Fine chemical business is fully booked: Apiqo Organics is already overbooked with no demand-side issues, contributing to the ₹120–150 crore expected from the fine chemical segment in FY27.
- Bizotic and Apiqo are profitable but margin-dilutive at the consolidated level: Both subsidiaries are doing well in absolute profitability, but their EBITDA margin percentages are under pressure, adding to the consolidated margin compression.
- H1 is structurally weaker than H2: The business follows a roughly 45:55 half-yearly split, so Q1 softness is partly seasonal and the revenue guidance of ₹380–400 crore for FY27 remains intact.
- Inventory build is an investment, not a cost: High inventory levels reflect process validation batches (minimum four batches required for DMF submission) that cannot be sold for 9–12 months until DMF approval and customer confirmation.
Punit Rasadia: "In pharma or chemical, it is not right measurement to measure the quarter-on-quarter basis. Better I suggest that you'll compare with the H1 or H2 basis."
Strategic Expansion: Subsidiaries, Capacity & New Businesses
- Remember India Health links marks entry into finished dosage formulations: The 63.98% stake acquisition was completed on 8 May 2026, adding tablet, capsule, and ointment manufacturing capabilities with a backward API supply chain that management expects will deliver margins better than 25%.
- Remember India is still in validation, not production: Maintenance, upgradation, and validation activity is ongoing; commercial operations are planned from Q4 FY27, with WHO-PQ approval expected by end of calendar year 2026 and meaningful revenue only from FY28.
- Share swap to make Apiqo and Bizotic wholly-owned is underway: The process has been initiated and intimated to the exchange; completion is expected by end of Q2 FY27, which will simplify the group structure.
- Anlon Biologics incorporated for peptides and biosimilars: The subsidiary will manufacture peptides (human, cosmetic, nutraceutical) and other bio products, kept separate from Anlon Healthcare due to different technology and regulatory requirements; own manufacturing expected to start by FY28, with revenue generation by FY28 Q4.
- Anlon Medicare enters surgical implants: The subsidiary will cover trauma, spine, and joint implants as a strategic extension of the pain management ecosystem; revenue generation expected by Q2 FY28.
- Pain management ointment filed with DCGI: A competitive product for Volini has been submitted for approval; a first-time-in-India launch is expected within one year, and the Remember India acquisition enables in-house manufacturing without third-party dependence.
- Organic capacity expansion of ~₹130 crore at Anlon site: Construction is already lined up to add ~1,200 MT capacity, funded by ~₹70 crore of debt and the remainder from internal accruals; commissioning is expected by Q1 FY28, subject to statutory approvals.
- Seven new DMF filings planned within FY27: These span additional therapeutic categories, with DMF compilation and filing activity already ongoing.
CDMO, Product Pipeline & R&D
- CDMO molecule timelines are unchanged: One molecule is expected to enter commercial supply by Q3 FY27, with two others by Q4 FY27 or Q1 FY28; process validations are ongoing and a further update is expected after Q3.
- Peptide products identified and developed at R&D level: Construction planning is underway, with commencement activity expected within two months and own manufacturing targeted for FY28.
- Anlon standalone is at peak capacity utilization: No further production increase is possible at the existing site, making the organic expansion the sole growth lever for the standalone entity; FY27 standalone revenue is expected around ₹180 crore, similar to the prior year.
Working Capital & Cash Flow
- Trade receivable days are elevated at 170–180 days: Management states this is normal for the pharma/API industry, where nominal payment terms are 90 days but actual collection runs 130–135 days; a reduction to 60–70 days is not considered feasible given industry norms of 150–160 days, and the company expects receivable days to remain in line with 170–180 days.
- Stricter payment discipline is being enforced: The company has changed payment terms with customers, is stricter on collections, and is not working directly with customers who do not pay on time; effects are expected to materialize during FY27.
- Positive operating cash flow targeted before FY27 end: Management is working toward achieving "some lower but positive case operating cash flow" by year-end, though the exact trajectory depends on the receivables tightening taking hold and better profitability on some products.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| EBITDA margin recovery | Normalize to 25–30% range | By H1 FY27 (Q2–Q3) |
| FY27 consolidated revenue | ₹350–400 crore | FY27 full year |
| FY28 consolidated revenue | ~₹700 crore, contingent on Anlon expansion completing on schedule | FY28 full year |
| Apiqo and Bizotic become 100% subsidiaries | Share swap process completed | By end of Q2 FY27 |
| Anlon site capacity expansion commissioned | ~₹130 crore CAPEX, ~1,200 MT added | By Q1 FY28, if everything goes well, subject to statutory approvals |
| Remember India commercial operations begin | Revenue generation starts | Q4 FY27 |
| CDMO molecule 1 commercial supply | First commercial supply | Q3 FY27 |
| CDMO molecules 2 and 3 commercial supply | Commercial supply | Q4 FY27 or Q1 FY28 |
| Pain management ointment launch | DCGI approval and first-time-in-India launch | Within one year |
| Anlon Biologics revenue generation | First revenue | FY28 Q4 |
| Anlon Medicare revenue generation | First revenue | Q2 FY28 |
| Positive operating cash flow | Some lower but positive operating cash flow | Before end of FY27 |
| Seven new DMF filings | Across additional therapeutic categories | Within FY27 |
| FY27 standalone Anlon revenue | ~₹180 crore | FY27 full year |
| FY27 PAT margin | 12–13%, described as conservative due to potential statutory approval delays | FY27 full year |
Key Metrics
| Metric | Q1 FY27 |
|---|---|
| Consolidated total income | ₹87.62 cr, vs ₹33.31 cr in Q1 FY26 |
| Consolidated EBITDA | ₹15.65 cr, vs ₹6.26 cr in Q1 FY26 |
| Consolidated PAT | ₹8.28 cr, vs ₹3.55 cr in Q1 FY26 |
| EBITDA margin | ~17%, down from prior year; raw material price surge and Remember India consolidation weighed on margins |
| FY27 revenue guidance | ₹350–400 cr, reiterated; Q1 at ₹87 cr, H2 expected heavier than H1 |
| FY27 EBITDA margin guidance | 25–27%, expected to normalize by Q3 FY27 as price revisions flow through; Q2 expected better than Q1 |
| FY27 PAT margin guidance | 12–13%, on a conservative basis; FY28 also expected 12–13% on a conservative basis |
| FY28 revenue expectation | ~₹700 cr, contingent on Anlon site expansion commissioning by Q1 FY28 |
| Installed manufacturing capacity | 1,400–1,600 metric tonnes per annum, post-acquisitions |
| Capacity utilization | 62.37%, on a consolidated basis; Anlon standalone at peak level, but can be increased at Apiqo and Bizotic |
| Anlon site expansion CAPEX | ~₹130 cr, funded via ~₹70 cr debt at 8.5–8.6% interest and internal accruals |
| Revenue mix – Apiqo | ~₹45 cr in Q1; FY27 expected ₹120–150 cr |
| Revenue mix – Anlon standalone | ~₹32 cr in Q1; FY27 expected ~₹180 cr |
| Revenue mix – Bizotic | ~₹12 cr in Q1; FY27 expected ~₹60 cr |
| Remember India Health links stake | 63.98% acquired, transaction completed 8 May 2026; revenue contribution not expected until Q4 FY27 or FY28 |
| Fine chemical and specialty chemical contribution | ₹120–150 cr expected in FY27 |
| Trade receivable days | 170–180 days; payment terms 90 days, actual collection 130–135 days; management noted industry norm is 150–160 days |
| Gross margin target | 40–45% |
| Target revenue CAGR | ~30% over the next three years |